American heart journal plus : cardiology research and practice最新文献

{"title":"Unraveling the genetic blueprint of coronary artery disease: The role of polygenic risk scores in risk prediction","authors":"Alaaeddine El Ghazawi ,&nbsp;Akl C. Fahed ,&nbsp;Nour Fawaz ,&nbsp;Yeva Fakih ,&nbsp;Samir Alam ,&nbsp;Marwan Refaat","doi":"10.1016/j.ahjo.2025.100712","DOIUrl":"10.1016/j.ahjo.2025.100712","url":null,"abstract":"<div><div>Cardiovascular diseases, and most notably coronary artery disease (CAD), carry a large burden of mortality and morbidity, highlighting the need for better risk prediction and prevention. Several risk scoring tools for CAD have been developed to improve early detection, reduce the risk of acute cardiac events, and ensure adequate monitoring and follow-up of high-risk individuals. One that seized attention, especially with the groundbreaking advancements in disease's genetic buildup, was the polygenic risk score (PRS) for CAD. It was developed for potentially improving risk prediction at an early age, with individualized patient care. Our review aims to review the latest advances in this field of polygenic risk prediction, highlighting background information about PRS, current evidence supporting the utility of PRS for CAD, challenges associated with its implementation, and its complementary role with the coronary artery calcium score (CAC). Our review demonstrates that PRS could be a strong predictive indicator of CAD, especially when combined with other clinical factors. However, concerns remain regarding its applicability to genetically diverse populations, the ethical and psychological challenges, and practical feasibility. Lastly, PRS can augment and predict CAC in terms of risk discrimination and reclassification. In conclusion, PRS is a valuable tool that is upscaling with wider adoption. This requires a proper handling of its associated challenges to better shape the future of individualized care.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"62 ","pages":"Article 100712"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145898131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2 inhibitor therapy and clinical outcomes in HIV-related cardiomyopathy","authors":"Hesham Sheashaa ,&nbsp;Ramzi Ibrahim ,&nbsp;Hoang Nhat Pham ,&nbsp;Kamal Awad ,&nbsp;Isabel G. Scalia ,&nbsp;Juan M. Farina ,&nbsp;Balaji Tamarappoo ,&nbsp;Cameron Holloway ,&nbsp;Reza Arsanjani ,&nbsp;Chadi Ayoub","doi":"10.1016/j.ahjo.2026.100722","DOIUrl":"10.1016/j.ahjo.2026.100722","url":null,"abstract":"<div><h3>Background</h3><div>HIV cardiomyopathy (HIV-CM) is associated with significant morbidity and mortality. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have benefits in heart failure (HF), but their role in the specialized population of HIV-CM is poorly understood.</div></div><div><h3>Methods</h3><div>Patients in the TriNetX Network with HIV-CM and SGLT2i therapy were compared to a propensity matched control group of patients with HIV-CM without SGLT2i use. The primary endpoint was all-cause mortality, secondary endpoints included all-cause hospitalizations, acute HF, stroke, acute myocardial infarction (MI), cardiac arrest, atrial fibrillation and ventricular tachycardia.</div></div><div><h3>Results</h3><div>In the total of 2606 included patients, SGLT2i therapy was associated with significant reduction in all-cause mortality (HR 0.475, 95%CI 0.337–0.671), all-cause hospitalization (HR 0.725, 95%CI 0.646–0.814). No significant differences were observed in the individual outcomes of acute HF, MI, stroke, or cardiac arrest.</div></div><div><h3>Conclusion</h3><div>SGLT2i use was associated with significant reductions in all-cause mortality and hospitalizations in patients with HIV-CM.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"62 ","pages":"Article 100722"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145980262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short dual antiplatelet therapy after PCI with Resolute Onyx drug-eluting stents in high bleeding risk patients: One-year outcomes from a South Asian cohort","authors":"Pankaj Jariwala ,&nbsp;Guna Sai Vallapuri ,&nbsp;Bharat Kumar Reddy Konda ,&nbsp;Sukesh Kumar Jangam","doi":"10.1016/j.ahjo.2025.100703","DOIUrl":"10.1016/j.ahjo.2025.100703","url":null,"abstract":"<div><h3>Background</h3><div>The optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) in patients with high bleeding risk (HBR) remains unclear. This study evaluated the safety and efficacy of a shortened DAPT strategy (3-month DAPT followed by ticagrelor monotherapy) in patients with HBR receiving Resolute Onyx zotarolimus-eluting stents (ZES).</div></div><div><h3>Methods</h3><div>This retrospective observational study was conducted at the Yashoda Hospitals in Hyderabad. A total of 150 HBR patients who underwent PCI with Resolute Onyx ZES between June 2023 and June 2024 were included in the study. All patients received DAPT (aspirin 75 mg + ticagrelor 90 mg BID) for three months, followed by ticagrelor monotherapy for nine months. The primary outcome was a composite of cardiac death or MI from three months to one year. The secondary endpoints included stent thrombosis, target lesion failure (TLF), target lesion revascularization (TLR), stroke, and bleeding events (BARC classification).</div></div><div><h3>Results</h3><div>The mean age was 75.5 years, and 42.3 % were female. Diabetes was observed in 33.5 % of patients, prior revascularization in 46.4 %, and acute coronary syndrome in 58.3 %. Most lesions were calcified (60.8 %) or complex (88.2 % B2/C lesions). The patients met an average of 1.9 HBR criteria, and 54.6 % met at least two criteria. The primary composite endpoint occurred in 5.7 % of the patients (cardiac death-2.3 %; MI-3.4 %). Definite/probable stent thrombosis occurred in 0.3 %, TLF in 3.0 %, clinically driven TLR in 1.7 %, stroke in 0.6 %, and BARC 1–3 bleeding in 2.1 %. No BARC 3–5 bleeding events were recorded.</div></div><div><h3>Conclusion</h3><div>In this real-world HBR cohort treated with Resolute Onyx ZES, a strategy of 3-month DAPT followed by ticagrelor monotherapy was associated with low rates of ischemic events and the absence of major bleeding at one year. These findings suggest a favorable safety–efficacy balance for DAPT de-escalation in carefully selected patients; however, this requires confirmation in larger, prospective studies.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"62 ","pages":"Article 100703"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145898132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticoagulants for the prevention and treatment of venous thromboembolism in humans exposed to microgravity: A hybrid systematic and narrative review","authors":"Adele Watfa ,&nbsp;Arwa Younis ,&nbsp;Andrew Winnard-Brewer ,&nbsp;Katie M. Greenlee ,&nbsp;Julia Ferrin ,&nbsp;Niraj Varma ,&nbsp;Jerry G. Myers Jr. ,&nbsp;Virginia Wotring ,&nbsp;Kenneth A. Mayuga","doi":"10.1016/j.ahjo.2026.100724","DOIUrl":"10.1016/j.ahjo.2026.100724","url":null,"abstract":"<div><h3>Importance</h3><div>Microgravity induces physiological changes that may predispose astronauts to venous thromboembolism (VTE), yet no studies have directly evaluated the safety or efficacy of anticoagulation in this environment.</div></div><div><h3>Objective</h3><div>To perform a systematic review of anticoagulant use for VTE prevention and treatment in microgravity-exposed individuals and, in the absence of eligible studies, to synthesize existing physiologic and terrestrial evidence relevant to VTE risk and thromboprophylaxis.</div></div><div><h3>Methods</h3><div>A comprehensive search of 13 biomedical and aerospace databases (MEDLINE, Embase, Scopus, Web of Science, Cochrane Library, CINAHL, NASA Technical Reports Server, ESA archives, <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>, NASA Life Sciences Data Archive, ISS Publications Archive, DLR database, NASA SS Research Database) was performed following PRISMA guidelines. Eligible studies included astronauts or individuals in microgravity analogs receiving pharmacologic anticoagulation for VTE prevention or treatment.</div></div><div><h3>Results</h3><div>The search yielded zero studies meeting predefined PICOS criteria. To contextualize this absence of evidence, we synthesized key physiologic findings from microgravity and ground-based analog studies demonstrating venous stasis, endothelial dysfunction, increased fibrinogen synthesis, altered platelet function, and hypercoagulability.</div></div><div><h3>Conclusions and relevance</h3><div>VTE appears rare in spaceflight, but the absence of direct evidence on anticoagulation underscores a critical research gap. Further studies are needed to evaluate anticoagulant safety and efficacy in microgravity, adapt risk assessment tools, and develop evidence-based protocols to safeguard astronaut health.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"62 ","pages":"Article 100724"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital phenotyping and ASCVD risk: An exploratory cross-sectional analysis using online behavioral data","authors":"Lauren Southwick ,&nbsp;Neil K.R. Sehgal ,&nbsp;Dena Torrente ,&nbsp;Veronica Murgulescu ,&nbsp;Devon Schroeder ,&nbsp;David A. Asch ,&nbsp;Lyle Ungar ,&nbsp;Nandita Mitra ,&nbsp;Peter Groenveld ,&nbsp;Stephen E. Kimmel ,&nbsp;Gary E. Weissman ,&nbsp;Sharath Chandra Guntuku ,&nbsp;Raina M. Merchant","doi":"10.1016/j.ahjo.2026.100717","DOIUrl":"10.1016/j.ahjo.2026.100717","url":null,"abstract":"<div><div>A retrospective, exploratory cross-sectional analysis exploring whether social media data is associated with cardiovascular disease (CVD) risk beyond traditional clinical models. While social media data may capture behavioral and social markers relevant to CVD, their associations with CVD risk remains uncertain.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"62 ","pages":"Article 100717"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetocardiography for noninvasive surveillance of rejection and cardiac allograft vasculopathy in heart transplant recipients","authors":"Christian Eskander ,&nbsp;Matthew Peters ,&nbsp;Dipankar Gupta ,&nbsp;Katelyn A. Bruno ,&nbsp;Juan R. Vilaro","doi":"10.1016/j.ahjo.2025.100704","DOIUrl":"10.1016/j.ahjo.2025.100704","url":null,"abstract":"<div><div>Heart transplantation is the definitive treatment for end-stage heart failure, yet long-term graft survival is hindered by two major complications: acute/chronic rejection (cellular or antibody mediated) and cardiac allograft vasculopathy (CAV). Standard surveillance is performed to screen for these issues and predominantly consists of cardiac catheterization with hemodynamics, endomyocardial biopsy and invasive coronary angiography, with intravascular ultrasound (IVUS) and coronary flow reserve. The use of IVUS increases the sensitivity for CAV detection. Overall, these procedures have associated morbidities, need anesthesia and have associated patient discomfort and substantial cost. Magnetocardiography (MCG), a noninvasive modality that measures cardiac magnetic fields, has emerged as a potential tool for early detection of complications in post-transplant patients. Unlike electrocardiography, MCG provides spatially resolved data on depolarization and repolarization, independent of body habitus or tissue conductivity. Early studies suggest that MCG can identify electrophysiologic abnormalities associated with both acute rejection and CAV, in some cases preceding histologic or angiographic confirmation. Rejection is reflected by alterations in magnetic dipole strength and repolarization heterogeneity, while CAV correlates with repolarization dispersion indices such as QTc heterogeneity and Magnetic Dispersion Velocity. Despite promising pilot data, MCG remains underutilized, largely due to small study sizes, lack of standardized interpretation, and limited availability of equipment. This review synthesizes the existing evidence, highlights potential advantages and limitations, and outlines future directions for integrating MCG into standard post-transplant surveillance protocols.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"62 ","pages":"Article 100704"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145980257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can magnetocardiography decrease ED overcrowding, increase hospital bed capacity, and save hospitals money?","authors":"Margarita E. Pena ,&nbsp;Sharon E. Mace ,&nbsp;Griffin Bleecker ,&nbsp;Kaitlin Kreuser Girard ,&nbsp;Praveen Mital ,&nbsp;Pawan Suri ,&nbsp;Robert E. Takla","doi":"10.1016/j.ahjo.2025.100705","DOIUrl":"10.1016/j.ahjo.2025.100705","url":null,"abstract":"<div><h3>Objectives</h3><div>The objectives of this study are to demonstrate the time and cost savings of magnetocardiography (MCG) compared to other noninvasive cardiac imaging (NCI) tests, specifically in regard to time, number of skilled healthcare personnel (HCP), and cost of skilled HCP, medications and supplies, including contrast agents and radiotracers required to perform each test.</div></div><div><h3>Design</h3><div>This is a multicenter study comparing the time, skilled HCP, and costs needed to perform MCG and other NCI from four urban and community hospitals.</div></div><div><h3>Outcome measures</h3><div>Time needed to perform each test, the number of skilled HCP required, and costs for labor, supplies/drugs and contrast agents/radiotracers.</div></div><div><h3>Results</h3><div>Median time in minutes for obtaining ETT 60, SE 75, DSE 75, MPI-SPECT 225, MPI-PET 180, cMRI 90, and cCTA 75, MCG 15. Median number of skilled HCP required for performing the NCI were ETT 1.5, SE 2.5, DSE 2.5, MPI-SPECT 3.0, MPI-PET 3.0, cMRI 2.5, cCTA 2, and MCG 1. Median skilled HCP and their costs was ETT $71.23, SE $150.43, DSE $153.91, MPI-SPECT $625.18, MPI-PET $403.62, cMRI $95.41, cCTA $138.03, and MCG $8.75.</div></div><div><h3>Conclusion</h3><div>There is a time, skilled HCP and cost savings by using MCG versus other NCI for the evaluation of chest pain. Further studies are needed to validate MCG as an alternative to other NCI so these benefits can be realized.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"62 ","pages":"Article 100705"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary artery disease in patients undergoing transcatheter aortic valve replacement: Current evidence and future directions","authors":"Bahaa El Deen Wehbeh ,&nbsp;Moied Al Sakan ,&nbsp;Jamil Francis ,&nbsp;Rachad Ghazal ,&nbsp;Samir Alam ,&nbsp;Fadi Sawaya","doi":"10.1016/j.ahjo.2025.100710","DOIUrl":"10.1016/j.ahjo.2025.100710","url":null,"abstract":"<div><div>Coronary artery disease (CAD) coexists frequently with aortic stenosis (AS), and the optimal management of CAD in patients undergoing transcatheter aortic valve replacement (TAVR) remains incompletely defined due to limited and heterogeneous evidence. This review aims to integrate the current evidence on the epidemiology and shared pathophysiology of CAD and AS, summarize the diagnostic algorithms for CAD in the TAVR population, and evaluates revascularization strategies with a focus on the timing of percutaneous coronary intervention relative to valve replacement. Current evidence suggests that while routine PCI in TAVR candidates for stable CAD may offer limited benefit, revascularization in patients with complex CAD or high anatomical burden may improve outcomes. This review further characterizes the incidence, proposed mechanisms, and prognostic significance of post-TAVR coronary events and outlines emerging strategies to optimize ischemic and procedural outcomes in this high-risk cohort.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"62 ","pages":"Article 100710"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145898133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Educational innovation in cardiovascular care: Developing a curriculum for women's cardiovascular health","authors":"Giorgia Borgarelli ,&nbsp;Cristiane C. Singulane ,&nbsp;Paul Montana ,&nbsp;Lucie Lefbom ,&nbsp;Hakinya Karra ,&nbsp;Kelsey Watts ,&nbsp;Kara Harrison ,&nbsp;Jennifer M. Choffel ,&nbsp;Christopher S. Ennen ,&nbsp;Aditya M. Sharma ,&nbsp;Kelly E. Wingerter ,&nbsp;Victor Soukoulis ,&nbsp;Patricia F. Rodriguez-Lozano","doi":"10.1016/j.ahjo.2025.100693","DOIUrl":"10.1016/j.ahjo.2025.100693","url":null,"abstract":"<div><div>Cardiovascular disease (CVD) is the leading cause of death among women in the United States, with significant knowledge gaps in sex-specific care among providers. To address this, we developed and implemented a structured, multidisciplinary women's cardiovascular health (CVH) curriculum within the cardiovascular fellowship program at the University of Virginia. The curriculum focused on women-specific cardiovascular health, including cardio-obstetrics, spontaneous coronary artery dissection (SCAD) and coronary microvascular disease (CMD), and encompassed didactic lectures and unique experiential learning through clinical work, research, and community outreach. This multidisciplinary approach enhances individualized care and prepares trainees to recognize and treat the unique cardiovascular needs of women. Continued development of such curricula is crucial for reducing morbidity and mortality disparities in CVD.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"61 ","pages":"Article 100693"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity burden among heart failure patients in an urban safety net hospital: Implications for GLP-1 agonist therapy","authors":"Tracey Yee ,&nbsp;Priya Gajjar ,&nbsp;Deepa M. Gopal ,&nbsp;Matthew Nayor","doi":"10.1016/j.ahjo.2025.100688","DOIUrl":"10.1016/j.ahjo.2025.100688","url":null,"abstract":"<div><h3>Introduction</h3><div>Novel obesity medications (glucagon-like peptide-1 [GLP-1] agonists) show promise for treatment of patients with obesity and heart failure (HF), especially with preserved ejection fraction (HFpEF). However, data are limited regarding the burden of obesity among HF patients in real-world samples.</div></div><div><h3>Methods</h3><div>We conducted a retrospective electronic medical record-based query of HF patients at a single urban safety net hospital system.</div></div><div><h3>Results</h3><div>In 1373 patients (mean age 67 ± 14 years, 59 % women) admitted for acute HF (563 [41 %] with HFpEF, 649 [47 %] with reduced ejection fraction, and 161 [12 %] without ejection fraction assessment), up to 64 % met eligibility criteria GLP-1 agonists compared with 42 % of control patients admitted for non-HF diagnoses. This was primarily driven by higher obesity prevalence.</div></div><div><h3>Discussion</h3><div>The majority of HF patients at an urban safety net hospital are eligible for GLP-1 agonist medications; allocation of these medications to a large patient population represents a major public health challenge.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"61 ","pages":"Article 100688"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145684872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}